Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) EBITDA (2016 - 2025)

Historic EBITDA for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to -$61.8 million.

  • Regenxbio's EBITDA fell 678.6% to -$61.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$178.0 million, marking a year-over-year increase of 2327.37%. This contributed to the annual value of -$223.4 million for FY2024, which is 1152.69% up from last year.
  • Per Regenxbio's latest filing, its EBITDA stood at -$61.8 million for Q3 2025, which was down 678.6% from -$70.9 million recorded in Q2 2025.
  • Regenxbio's 5-year EBITDA high stood at $292.7 million for Q4 2021, and its period low was -$86.1 million during Q1 2022.
  • Its 5-year average for EBITDA is -$40.5 million, with a median of -$59.2 million in 2023.
  • Within the past 5 years, the most significant YoY rise in Regenxbio's EBITDA was 72465.65% (2021), while the steepest drop was 80369.7% (2021).
  • Quarter analysis of 5 years shows Regenxbio's EBITDA stood at $292.7 million in 2021, then tumbled by 119.5% to -$57.1 million in 2022, then decreased by 4.95% to -$59.9 million in 2023, then rose by 14.29% to -$51.3 million in 2024, then fell by 20.45% to -$61.8 million in 2025.
  • Its EBITDA stands at -$61.8 million for Q3 2025, versus -$70.9 million for Q2 2025 and $6.1 million for Q1 2025.